The effect of withdrawal of oral iron supplementation on airway microbiology and outcomes in people with Cystic Fibrosis
- Conditions
- Cystic FibrosisRespiratory tract infectionRespiratory - Other respiratory disorders / diseasesHuman Genetics and Inherited Disorders - Cystic fibrosisInfection - Studies of infection and infectious agents
- Registration Number
- ACTRN12612000146897
- Lead Sponsor
- Dr Daniel Smith
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot yet recruiting
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Diagnosis of Cystic Fibrosis
Aged Greater Than 18 years Old
Competant to give written informed consent
Able to Complete written questionnaires in the English Language
Currently taking oral iron supllementation but with normal iron stores as indicated by a soluble transferrin receptor / Log ferritin ration of less than 1.54
Exclusion Criteria
Pregnancy
Current History of Malignancy
Severe Symptomatic anaemia which in the opinion of the treating physicians requires ongoing iron supplementation
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Systemic and Sputum Iron Content<br><br>Tools: Blood assessment of total iron, ferritin, soluble transferrin receptors, and transferrin saturations will be measured by ELISA floowing local pathology laboratory standard practices.<br><br>Sputum iron concentration will be measured by Inductively coupled plasma mass spectrometry (ICP-MS)[0, 12, 24, 36, and 52 Weeks]
- Secondary Outcome Measures
Name Time Method Sputum Microbiology[0, 12, 24, 36, and 52 Weeks];Exacerbation Frequency<br><br>Tools: Recording of number of courses of antibiotics, total number of days of antibiotic treatment, Number of hopsital admissions[52 Weeks];Daily Symptom Score[0, 12, 24, 36, and 52 Weeks];Lung Function<br><br>Tests used: FEV1, FVC, MMEF[0, 12, 24, 36, and 52 Weeks]